Taking its first drug candidate into clinical development in non-alcoholic steatohepatitis (NASH), Nimbus Therapeuticsisn’t concerned about the increasing number of companies looking at this unmet medical need because it is content to let other players sort out the pivotal trial pathway.
You could call it a “non-first-mover” advantage, but Nimbus doesn’t think it needs to be first to market in NASH because its candidate, currently in IND-enabling studies, is a first-in-class...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?